Replimune Group, Inc.

REPL

US76029N1063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-12 EDT			5-day change	1st Jan Change
8.880 ^USD	+3.02%		-6.23%	-8.64%

06-01	Replimune Says Evaluating RP2 for Metastatic Uveal Melanoma in Phase 2/3 Trial; Shares Up Pre-Bell	MT
05-31	Replimune Group Presents Final First-In-Human Data for RP2 in Advanced Solid Tumors	CI

Top Midday Decliners

Published on 04/13/2026 at 02:25 pm EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Replimune Group, Inc.

06-01	Replimune Says Evaluating RP2 for Metastatic Uveal Melanoma in Phase 2/3 Trial; Shares Up Pre-Bell	MT
05-31	Replimune Group Presents Final First-In-Human Data for RP2 in Advanced Solid Tumors	CI
05-30	Replimune Group says RP1 plus Nivolumab achieves median overall survival of 32.9 months in anti-PD-1-failed melanoma	RE
05-30	Replimune Group Presents Three-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial of RP1 Plus Nivolumab in Patients with Anti-PD-1-Failed Melanoma	CI
05-29	Replimune Group Announces Planned RP1 BLA Resubmission Following Discussion With FDA	CI
05-29	Wedbush Adjusts Price Target on Replimune Group to $6 From $2, Maintains Neutral Rating	MT
05-29	Top Midday Gainers	MT
05-29	Replimune to Resubmit Melanoma Therapy Application for FDA Approval	MT
05-29	Replimune Plans to Resubmit Melanoma Therapy Application for FDA Approval	MT
05-29	Replimune announces planned RP1 BLA resubmission following productive discussion with FDA	RE
05-29	Replimune gets third chance at US approval for skin cancer drug	RE
05-29	Replimune gets third try at FDA approval after Makary departure - WSJ	RE
05-29	Replimune expected to announce agreement with FDA to resubmit its advanced melanoma treatment for approval - WSJ	RE
05-13	Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms	RE
05-12	Trump says US FDA Commissioner Makary is out	RE

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

Employees

479

Sector

Biotechnology & Medical Research

More about the company